Brain MRI T2 lesions (B-T2L) at time of CIS are a well-known risk factor for developing SPMS. However, longitudinal data studying the influence of cervical spinal cord T2 lesions (SC-T2L) are lacking. The prognostic value of SC-T2L on MRI performed at the time of CIS was assessed in a retrospective study of prospectively gathered data of patients with a CIS suggestive of demyelinating disease. All participants had a brain and cervical spinal cord MRI at diagnosis. Dr Laura Lacruz-Ballester (Health Research Institute La Fe, Spain) presented the results.
The study cohort consisted of 242 patients, with a mean age of 32 years and 71.1% women. Mean follow up was 12.7 years. Of these 242 patients, 205 (85.6%) were treated; 87 (41.8%) began treatment after the first relapse, and 120 (58.2%) after the second relapse. Of the CIS patients, 224 (92.6%) had a second relapse; 36 (14.9%) evolved to SPMS. The median total number of B-T2L lesions was higher in SPMS (20.5) than in relapsing-remitting MS/CIS patients (11.9; P=0.009). So was the number of SC-T2L lesions (1.75 vs 1.0; P=0.00005). Dr Lacruz-Ballester said: “In a regression model, adjusting for sex, age, treatment initiation at CIS, B-T2L, SC-T2L, and the presence of oligoclonal bands, SC-T2L was the only independent factor to predict conversion to SPMS, with an odds ratio of 2.2 (95% CI 1.06–4.97).”
Dr Lacruz-Ballester concluded that this data should stimulate studies of how spinal cord lesions can trigger neurodegeneration in progressive MS, for example by inducing corticospinal tract atrophy, or via a chronic inflammatory mechanism.
- Lacruz-Ballester L. Cervical spinal cord T2 lesions independently predict early conversion to secondary progressive multiple sclerosis: a longitudinal 10-year study. OP137, ECTRIMS 2021 Virtual Congress, 13–15 October.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Natural killer-like CD8+ T cells as a reservoir of clonal cells related to MS activity Next Article
Changes in GABA-receptor binding among cognitively impaired MS patients »
« Natural killer-like CD8+ T cells as a reservoir of clonal cells related to MS activity Next Article
Changes in GABA-receptor binding among cognitively impaired MS patients »
Table of Contents: ECTRIMS 2021
Featured articles
Preliminary data shows positive results of ATA188 for progressive MS
COVID-19
MS patients at risk of hampered immune response after vaccination
Immunotherapy in MS does not influence COVID-19 severity and mortality
Anti-CD20 antibodies associated with worse COVID-19 outcomes
ECTRIMS-EAN consensus on vaccination in MS patients
Experimental Treatments
The role of astrocyte phenotypes in acute MS lesions
Promising results of intrathecal MSC-NTF cells in progressive MS
Preliminary data shows positive results of ATA188 for progressive MS
Evobrutinib reduces relapses and MRI lesion activity
Primary endpoint of opicinumab for relapsing MS not met in AFFINITY trial
Elezanumab did not outperform placebo in progressive and relapsing MS
Ibudilast reduced retinal atrophy in primary progressive MS
Treatment Trials and Strategies
ECTRIMS/EAN Clinical Guidelines on MS treatment: an update
Rituximab most effective initial MS therapy in Swedish real-world study
Ublituximab meets primary endpoint for relapsing MS
Dynamic scoring system aids decision to switch MS therapies early
Long-term suppression of MRI disease activity with ocrelizumab
Stopping DMT: when or if at all?
Biomarkers
Early predictors of disability progression in paediatric-onset MS
High-sensitive biomarker detection in MS via novel ELISA assay
Cortical lesions predict cognitive impairment 20 years after MS diagnosis
Applicability of sNfL measurement in clinical practice
MRI more sensitive for disease activity than relapses in SPMS
Imaging
Changes in GABA-receptor binding among cognitively impaired MS patients
T2 lesions independently predict early conversion to SPMS
Natural killer-like CD8+ T cells as a reservoir of clonal cells related to MS activity
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Eculizumab, satralizumab, or inebilizumab for NMOSD?
Long-term efficacy of satralizumab for NMOSD
Long-term efficacy data: inebilizumab for NMOSD
Progressive MS
Charcot Award 2021: Progressive MS, a personal perspective
Top score poster: Meta-analysis on the effect of DMTs
Cortical lesions predict disease progression and disability accumulation
Ocrelizumab shows long-term benefits in primary progressive MS
Other
WNT9B-gene variant associated with doubled relapse risk in MS
Melatonin associated with improved sleep quality in MS patients
“Expanded Disability Status Scale 0 is not normal”
Personality trait alterations in MS patients
Related Articles
June 16, 2021
Dysmetabolism may drive MS progression
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com